As we reported in March, the Federal Government pledged $275 million to research relating to COVID-19. On April 23, 2020, an additional $1.1 billion in funding was announced and includes funding for:

  • Research and Data:
    • $114.9 million for research to accelerate the development, testing, and implementation of medical and social countermeasures to COVID-19. This will be provided through the Canadian Institutes of Health Research.
    • $40 million for the Canadian COVID-19 Genomics Network for COVID-19 viral and host genome sequencing research.
    • $10 million to improve data monitoring coordination of pandemic-related data across the country.
  • Vaccine Development:
    • $600 million to support COVID-19 vaccine and therapy clinical trials led by the private sector, and Canadian biomanufacturing opportunities. This will be provided through the the Strategic Innovation Fund.
    • $23 million for the Vaccine and Infectious Disease Organization-International Vaccine Centre to accelerate development of a vaccine against COVID-19.
    • $10.3 million over two years, and $5 million ongoing, to support the Canadian Immunization Research Network in conducting vaccine-related research and clinical trials, and monitoring of vaccine safety and effectiveness.
  • Manufacturing infrastructure:
    • $29 million to improve infrastructure for the production of vaccines at the National Research Council of Canada's Human Health Therapeutics facility in Montreal.

Separately, the government also announced an additional $675,000 through the Stem Cell Network for research into a potential cell therapy to reduce the impacts and severity of acute respiratory distress associated with COVID-19.


About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.

Law around the world
nortonrosefulbright.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.